Obinutuzumab combined with lenalidomide demonstrated a 2-year progression-free survival (PFS) rate of 93.3% in untreated high tumor burden follicular lymphoma (FL).
The complete response (CR) rate at 30 months reached 89.7%, indicating deep and durable remissions.
The safety profile was manageable with mostly grade 1-2 adverse events; grade ≥3 neutropenia and rash were the most frequent serious toxicities.
This chemo-free regimen harnesses enhanced antibody-dependent mechanisms and immunomodulation, representing a promising therapeutic approach for frontline FL treatment.
